Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OSRH vs IBO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–2 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: OSRH 1 – 2 IBO (3 Tie) Matrix Metrics: OSRH 2 – 7 IBO

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over OSR Holdings, Inc. (OSRH) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). OSRH carries a Unified Composite Score of 45.0/100 (HOLD) at $0.12 (N/M Forward P/E, -960.8% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin).

  • Composite vs. Pillar Nuance: While OSRH currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -960.8% operating margin) and revenue trajectory (+16.7% vs. -72.2% YoY).
  • Technical & Structure Timing Caution: OSRH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OSRH vs IBO
OSRH NASDAQ
OSR Holdings, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.12
-53.4% 1D
Market Cap $8.8M
TTM Revenue $1.8M
Forward P/E N/M
Beta / 30D Vol 0.57β · 390% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 33.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.2%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $0.38 · SMA50: $0.38
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
TTM Revenue $2.6M
Forward P/E N/M
Beta / 30D Vol -6.72β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52

6-Pillar Scorecard Institutional Category Breakdown (OSRH 1 – 2 IBO)

Columns: Metric · OSRH · IBO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue 6.7x 17.4x
2. Growth & Scale IBO
Revenue Growth (YoY) -72.2% +16.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.8M $2.6M
Market Cap $8.8M $44.4M
3. Profitability & Quality OSRH
Gross Margin 33.4% N/A
Operating Margin -960.8% -12621.0%
Net Profit Margin 0.0% 4247.4%
Return on Equity (ROE) -11.3% 71.2%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$5.4M -$284M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.4M Net Debt (0.05x D/E) $1.18 Book/Sh · 71.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OSRH (2) vs IBO (7)
Institutional Metric OSRH IBO Criterion Row Edge
Market Capitalization
Scale
$8.8M $44.4M Larger Scale IBO
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-72.2% +16.7% Higher Growth IBO
Operating Margin (TTM)
Profitability
-960.8% -12621.0% Higher Margin OSRH
Net Profit Margin
Profitability
0.0% 4247.4% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
-11.3% 71.2% Higher ROE IBO
52-Week Range Position
Momentum
3% ($0–$1) 67% ($0–$7) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
0.57β · 390% Vol -6.72β · 120% Vol Lower Realized Risk IBO
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite OSRH
Trailing 12M Revenue (USD)
Operating Scale
$1.8M $2.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
33.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.7x EV/Rev N/M PEG · 17.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.4M ($3.4M Net Debt (0.05x D/E)) -$284M EBITDA ($1.18 Book/Sh · 71.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +79.63 pp
OSRH: -73.1% · IBO: +6.53%
3M Horizon IBO +66.34 pp
OSRH: -76.46% · IBO: -10.12%
6M Horizon IBO +77.98 pp
OSRH: -73.39% · IBO: +4.59%
1Y Horizon IBO +69.62 pp
OSRH: -79.38% · IBO: -9.76%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OSRH Revenue IBO Revenue OSRH Op. Margin IBO Op. Margin Margin Leader
FY2022 N/A $0M N/A -6808.0% IBO
FY2024 $0M N/A -331.2% N/A OSRH
FY2025 $0M $0M -631.0% -13381.2% OSRH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OSRH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OSRH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OSRH Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $8.8M market capitalization and -960.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $44.4M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OSRH vs IBO Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over OSR Holdings, Inc. (OSRH) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). OSRH carries a Unified Composite Score of 45.0/100 (HOLD) at $0.12 (N/M Forward P/E, -960.8% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While OSRH currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -960.8% operating margin) and revenue trajectory (+16.7% vs. -72.2% YoY). Technical & Structure Timing Caution: OSRH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBO leads the Growth & Scale pillar: OSRH posts -72.2% YoY revenue growth and +0.0% YoY earnings growth on $1.8M TTM revenue (33.4% gross margin, -960.8% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). Across the 3-period historical trajectory (FY2022 to FY2025), OSRH cumulative revenue shifted N/A while IBO shifted N/A. In operating R&D and SG&A reinvestment, OSRH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.

OSRH and IBO trade at balanced relative valuation multiples. OSRH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.7x EV/Revenue (unreported FCF margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OSRH (-11.3% ROE) versus IBO (71.2% ROE) capital efficiency.

In options market volatility and institutional positioning, OSRH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.57β · 390% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.